Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Pawel KermerChristoph C EschenfelderHans-Christoph DienerMartin GrondYasser AbdallaAlexej AbrahamKatharina AlthausGebhard BecksJörg BerrouschotJörg BerthelFelix J BodeLothar BurghausHakan CangürMichael DaffertshoferSebastian EdelbuschJürgen EggersRüdiger GerlachKlaus GröschelFlorian Große-DresselhausAlbrecht GüntherClaus G HaaseCarl-Albrecht HaenschAndreas HarloffJoseph G HeckmannValentin HeldMaren HieberAndreas KauertRolf KernThomas KerzMartin KöhrmannPeter KraftPeter KühnleinJan LattaElke LeinischArne LenzChristoph LeithnerTobias Neumann-HaefelinMathias MäurerWolfgang MüllgesChristian H NolteMark ObermannSomeieh PartowiPeer PatzschkeSven PoliUlrich PulkowskiJan Christoph PurruckerTorsten RehfeldtPeter A RinglebJoachim RötherRaluca RossiHazem El-SabassyOliver SauerGabriele SchackertNiklas SchäferPeter D SchellingerAndreas SchneiderRamona SchuppnerStefan SchwabOlav SchwarteRüdiger J SeitzSebastian SengerYogesh P ShahEckhart SindernPaul SparenbergThorsten SteinerKristina SzaboChristian UrbanekBettina von SarnowksiKarin WeissenbornPeter WieneckeKarsten WittRobert WruckSilke WunderlichPublished in: International journal of stroke : official journal of the International Stroke Society (2020)
Administration of rt-PA after reversal of dabigatran activity with idarucizumab in case of acute ischemic stroke seems feasible, effective, and safe. In dabigatran-associated intracranial hemorrhage, idarucizumab appears to prevent hematoma growth and to improve outcome.